The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Co. Advancing Drug Class With Broad Potential

Research Report
  ()
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

  ()
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report
  ()
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report
  ()
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

Biopharma Co. Transforming Injected Drugs Into Pills

Research Report
  ()
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion
  ()
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Two Talks On New Cancer Drug Slated for Meeting This Week

Research Report
  ()
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

  ()
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.

Expert Rates Pharma Co. An Immediate Buy

Contributed Opinion
  ()
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.

FDA OKs Biopharma to Trial New Cell Therapy

Research Report
  ()
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.

Delay in New Drug Filing Now Could Yield Benefits Later

Research Report
  ()
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.

ACC Recommends Approved Drug for Lowering LDL

Research Report
  ()
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula

  ()
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.

First Data Due by Year End 2022 From Study of New HAE Drug

Research Report
  ()
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.

New Schizophrenia Drug Has Chance of Getting FDA Approved

Research Report
  ()
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report.

Hedge Fund Doubles Position in Biotech Co.

  ()
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price a 560% increase from the unit price in its recent placement.

Expert Sees Even More 'Good News' From Pharma Co.

Contributed Opinion
  ()
Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.

Biotech Co. Has Multiple Shots on Goal

Research Report
  ()
This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report.

Price Target on Cancer Drug Co. Boosted

Research Report
  ()
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report.

Showing Results: 51 to 75 of 147 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe